



Media Release

9 February 2026

SPONTAN® now available

Medical experts: Erectile Dysfunction (ED) is more prevalent and severe with age

News update:

- Leading Australian medical experts are driving public awareness and conversation about the increased severity and prevalence of sexual issues in men aged 65+, with a focus on Erectile Dysfunction (ED).
- Men in their 40's have about a 40% chance of experiencing some form of ED, with prevalence increasing about 10% per decade thereafter¹.
- A common, but treatable part of aging, ED has attracted interest from Australian innovators who are optimising the delivery of an established class of oral tablets called PDE5 inhibitors with a ground-breaking new nasal spray called SPONTAN®.
- [A Phase II Clinical Trial is now recruiting in Sydney NSW](#), with an immediate focus on screening potential participants who are healthy men 65+.

9 February 2026, Australia | Leading Australian medical experts are driving advocacy efforts on behalf of men who experience sexual function issues as they get older, with a focus on Erectile Dysfunction (ED) which impacts the lives of more than 40% of men by the time they reach the age of 40.

Erectile dysfunction (ED) is a condition in which a person is unable to get or keep an erection firm enough for satisfactory sexual intercourse. ED can be a short or long-term problem, contributing to relationship breakdowns and mental health issues.

LTR Pharma Scientific and Clinical Advisor, A/Professor Darren Katz, said it is not unexpected for sexual function to change with age.

"It is very common to notice a decline in sexual performance with age. Erections typically take longer to develop, may be less rigid, and more sensitive to stress, fatigue, or distraction. Recovery time between erections also increases. Importantly, these changes do not mean a man's sexual desire disappears or that satisfying sex is no longer possible. Many men remain sexually active well into later decades, but they may require more stimulation, more time, or medical support," said A/Prof Katz.

"The key issue is whether these changes are bothering or distressing to the man or his partner. If erectile difficulties are affecting quality of life or relationships, proper medical evaluation and treatment are appropriate courses of action."

Erectile dysfunction is one of the most common chronic conditions affecting men, yet treatment options have changed surprisingly little over the past two decades. While oral medications (PDE5 inhibitors) have helped millions of men, they don't work well for everyone, especially in older men and those with vascular disease, diabetes, or complex medical profiles.

"There is a clear need for innovation that focuses on faster onset, greater reliability, improved tolerability, and treatment options that better fit real-world sexual behaviour. New delivery methods, such as intranasal therapies,

¹ <https://pmc.ncbi.nlm.nih.gov/articles/PMC5313305/>



are now being explored to address these gaps. The goal isn't to replace existing treatments, but to expand the toolbox so therapy can be better tailored to the needs and lifestyles of individual patients," said A/Prof Katz.

SPONTAN's unique nasal delivery technology bypasses the digestive system and is designed to overcome the issues of oral tablets for ED by having a significantly faster onset of action within 10 minutes. SPONTAN has already been proven to support rapid absorption and faster onset of action compared to oral PDE5 inhibitors (i.e. vardenafil, sildenafil, tadalafil), together with a better safety profile.

Oral ED PDE5 medications are absorbed through the gastrointestinal tract and then pass through the liver before reaching the systemic circulation, a process known as first-pass metabolism. Therefore, people require higher doses to reach a blood level at which the drugs can achieve positive effects. Higher doses can also increase the chance of side effects. Food intake and other factors affecting gut absorption, as well as interactions with other medications, can also influence how much drug is available and how quickly it works.

"Older men experience common challenges with lower-dose Viagra, Cialis, and other PDE5 therapies. They can be less reliable or less predictable than they were earlier in life. This is often due to a combination of factors — including reduced penile blood flow from vascular disease, diabetes, hypertension, and the effects of multiple medications. Some men also experience side effects such as headaches, flushing, reflux, which can limit increasing the dose to get the desired result. As a result, older men may report delayed onset, inconsistent response, or a feeling that the medication sometimes works and sometimes doesn't, which can be frustrating and impact confidence and spontaneity," said A/Prof Katz.

Men aged 65+ in Australia are now being recruited to participate in a Phase II clinical study at ScientiaClinical Research in Sydney NSW to trial a ground-breaking new nasal spray for the treatment of Erectile Dysfunction (ED) **SPONTAN®**, which is also being prescribed to eligible participants under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS).

To learn more about SPONTAN and/or to find a prescribing clinician, please visit spontan.life

- This is not an ASX announcement and has not been lodged with the Australian Securities Exchange -

MEDIA CONTACT

Haley Chartres
H^CK Director
e. haley@hck.digital
m. +61 423 139 163

MEDIA RESOURCES

- **IMAGES:** Click here to access images of SPONTAN®.
- **ANIMATION:** Click here to view a short animation, demonstrating the potential mechanism of action of SPONTAN®.



EXPERT SPOKESPERSON - AVAILABLE ON REQUEST

LTR Pharma Scientific and Clinical Advisor, Associate Professor Darren Katz, is a Clinical Associate Professor in the Department of Surgery at the University of Melbourne and Medical Director of Men's Health Melbourne. He directs Australia's only Prosthetic and Microsurgical Fellowship, training international urologists in advanced surgical techniques. A/Prof Katz completed his specialist urological training with the Royal Australasian College of Surgeons and undertook advanced fellowships at Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical Center in New York. He is the immediate past Leader of the Andrology Special Advisory Group to the Urological Society of Australia and New Zealand (USANZ) and plays a key role in developing national clinical guidelines for erectile dysfunction, PSA screening, and male infertility.

PATIENT SPOKESPEOPLE - AVAILABLE ON REQUEST

Selected case studies are available to discuss the lived experience of Erectile Dysfunction (ED). These case studies have not undertaken treatment with SPONTAN®.

ABOUT LTR PHARMA

LTR Pharma is a commercial-stage pharmaceutical company delivering innovative therapies to address significant unmet medical needs through its proprietary intranasal drug-delivery platform. The Company has successfully commercialised its rapid-acting treatment technology in Australia and is expanding access whilst advancing regulatory pathways in the US and other key markets.

LTR's lead products, **SPONTAN®** and **ROXUS®**, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is now advancing **OROFLOW®**, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function.

Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated, patient-centric treatments that enhance quality of life.